When Better Blood Sugar Control Causes Nerve Pain: What to Know About TIND

Treatment-induced neuropathy of diabetes, or TIND, is an uncommon nerve-related side effect that can develop when blood sugar levels are brought down too quickly. Unlike typical diabetic nerve damage, which develops gradually from years of high blood sugar exposure, TIND appears suddenly—usually within weeks of starting intensive glucose control.

The condition causes acute nerve pain and dysfunction, most commonly in the feet, legs, and lower back. Symptoms can be severe and include sharp, electric shock-like sensations. TIND is considered an iatrogenic condition, meaning it results from medical treatment itself, not from the underlying diabetes.

A 19-year-old with Type 1 diabetes who had struggled with high blood sugar levels for a decade (with an HbA1c of 13.7%) started using a hybrid closed-loop insulin pump system. This advanced technology helped lower his HbA1c dramatically—by 6.3% in just six weeks.

Within that same timeframe, he developed severe, burning nerve pain in his lower legs, feet, and upper back. Testing confirmed he had developed a length-dependent sensorimotor axonal polyneuropathy—essentially, nerve fiber damage affecting sensation and movement. His pain didn't improve with duloxetine, a common nerve pain medication, but did respond well to gabapentin. Over four weeks, his symptoms improved significantly. To prevent further complications, his doctors slowed his pace of glucose lowering by switching him to a less intensive insulin regimen.

The exact biological mechanism behind TIND isn't fully understood, but research suggests that rapid changes in glucose levels—especially sudden drops from very high baseline levels—may create metabolic stress that damages nerve fibers. The sharp, sudden shift in the body's metabolic environment appears to be the key trigger.

Advanced insulin delivery systems, while highly effective at improving blood sugar control, can sometimes lower glucose levels faster than the body's nerves can safely tolerate. This doesn't mean the technology is bad—it's a powerful tool—but it highlights the importance of individualized, gradual approaches to glucose management.

People with very high baseline HbA1c levels who start intensive glucose management are at higher risk for TIND. If you fall into this category and are beginning new insulin therapy or technology, pay close attention to how you feel.

Warning signs include sharp, electric shock-like pain; burning sensations; or tingling in your feet, legs, or back that develops soon after starting intensive blood sugar control. If you experience these symptoms, contact your doctor right away. TIND requires medical attention and may mean adjusting your treatment plan to lower glucose levels more gradually.

If you have very high blood sugar levels and are considering intensive management, talk with your diabetes care team about a gradual approach to glucose lowering—even with advanced systems like hybrid closed-loop pumps. Close monitoring and individualized adjustments to your treatment plan can help reduce the risk of nerve complications.

This case reinforces an important principle: faster is not always better in diabetes management. A thoughtful, personalized approach that considers your unique starting point and monitors for side effects offers the best balance of safety and effectiveness.

Source: International medical case reports journal. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.